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Microcytic anemia is frequently due to iron deficiency (IDA) or 
thalassemia. 
Other causes are Anemia of  chronic disease (rheumatoid arthri-
tis, Hodgkin lymphoma) and hereditary or acquired sideroblastic 
anemia or lead poisoning. Both diseases are endemic; represent a 
problem of  public health particularly in the developing countries.
The World Health Organization (WHO) has recently highlighted 
their growing concern about anemia, affecting an estimated 2000 
million people, 50% of  the cases caused by iron deficiency. Iron 
deficiency remains the most prevalent micronutrient deficiency 
worldwide[1].
Iron deficiency is one of  the leading risk factors for disability and 
death worldwide; it may result from insufficient iron intake or 
menstrual blood loss in women of  childbearing age, or chronic 
blood loss in the gastrointestinal tract in the case of  elderly sub-
jects. The consequences for affected individuals and the econom-
ic productivity of  societies are substantial. 
The high prevalence of  iron deficiency in the developing world has 
substantial health and economic costs, including poor pregnancy 
outcome, impaired school performance and decreased productiv-
ity. WHO estimates that 39% of  children younger than 5 years, 
48% of  children between 5 and 14 years, 42% of  all women, and 
52% of  pregnant women in developing countries are anaemic, 
with half  of  them having iron deficiency anemia. According to 
WHO, the frequency of  iron deficiency in developing countries is 
about 2∙5 times that of  anaemia. Iron deficiency is also common 
in women and young children in industrialized countries [2].
Nutritional iron deficiency arises when physiological requirements 
cannot be met by iron absorption from diet. Human life cycle in-
cludes two phases in which optimal nutritional iron is critically 
important: pregnancy and early childhood. Pregnancy because of  
the risk of  maternal death, preterm labor, low birth weight, and 
neonatal mortality and early childhood due to adverse effects on 
cognitive, motor, and emotional development that may only be 
partially reversible.In elderly persons anemia may be caused by a 
variety of  potentially contributing etiologies: nutritional, anemia 
of  chronic inflammation or renal disease [3].
Microcytic anemia in the case of  thalassemia results from im-
paired globin chain synthesis and decreased Hemoglobin (Hb) 
synthesis. 
Structural Hb variants are typically due to point mutations in a 
globin gene that produces a single amino acid substitution in a 
globin chain. Thalassemias, in contrast, result from quantitative 
underproduction of  globin chains.
Inherited Hb disorders such as Hb variants and thalassemias were 
originally characteristic of  the tropics and subtropics but are now 
common worldwide. Non-endemic countries such as Northern 
Europe and North America are also facing health issues due to 
Hb disorders as a result of  demographic changes caused by mi-
gration of  ethnic minority groups with a high frequency of  muta-
tions [4].
Because heterozygotes have a survival advantage after malaria in-
fections, the inherited hemoglobinopathies are the most common 
monogenetic diseases and approximately 7% of  the world popu-
lation is carrier of  such disorders. The prevalence of  Hb disor-
ders ranges from 0.3 to 25 per 1000 live births and Hb disorders 
are considered as a significant health care problem worldwide.
Thalassemia syndromes are among the most common genetic dis-
orders worldwide, with 1.7% of  the world’s population carrying 
thalassemic genes. In endemic countries the risk of  homozygosity 
is high and there it represents a major public health problem. The 
β-thalassemias have an estimated annual incidence of  sympto-
matic individuals of  1 in 100,000 throughout the world and 1 in 
10,000 people in the European Union. Data from recent epidemi-
ological surveys indicate that in Europe there are approximately 
15,000 subjects with transfusion-dependent thalassemia major [5].
Most of  the Hb variants and thalassemias are of  limited clini-
cal relevance, but severe forms of  thalassemia may produce seri-
ous clinical manifestations and may result in disabilities and even 
death in the first years of  life.
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The laboratory challenge is to detect the clinically significant Hb 
disorders and to identify them accurately. Since the pioneering 
study of  Pauling in 1949, in which the different electrophoretic 
mobilities of  sickle cell anemia  (Hb S) and normal Hb were de-
scribed, nearly 1100 Hb variants and 400 thalassemias affecting 
the α, β, γ and δ-globin chains have been identified.
Thalassemias are characterized by insufficient or absent synthe-
sis of  the  globin chains. An imbalanced production of  one of  
the globin chains leads to accumulation and precipitation of  un-
paired globin chains and consequently to ineffective erythropoie-
sis and hemolysis. Characteristically, patients affected with α- or 
β-thalassemia show microcytic hemolytic anemia. 
Clinically, three main forms have been described: thalassemia 
major, intermedia, and minor. Individuals with thalassemia major 
usually show severe anemia within the first 2 years of  life and 
require regular transfusions during their whole life. This therapy 
leads to iron overload and complications including endocrine 
complications (growth retardation, failure of  sexual maturation, 
diabetes mellitus, and insufficiency of  the parathyroid, thyroid, pi-
tuitary, and less commonly, adrenal glands), myocardiopathy, liver 
fibrosis, and cirrhosis.
Prognosis for individuals with β-thalassemia has improved sub-
stantially in the past 20 years following recent medical advances 
in transfusion, iron chelation, and bone marrow transplantation 
therapy. However, cardiac disease remains the main cause of  
death in patients with iron overload.
Usually, patients with thalassemia intermedia develop moderate 
anemia later in life and do not require regular transfusions. Main 
clinical features in these patients are hypertrophy of  erythroid 
marrow with enhanced medullary and extramedullary hemat-
opoiesis and its complications. Thalassemia minor is clinically 
asymptomatic, but some subjects may have moderate anemia and 
some splenomegaly. 
While the majority of  patients show significant microcytosis and 
some have borderline anemia, the hallmark of  β-thalassemia mi-
nor is an increase of  Hb A2 that distinguishes it from other micro-
cytic conditions like iron-deficiency.
The diagnosis of  β-thalassemia involves measuring HbA2 concen-
tration of  lysed red cells via high-performance liquid chromatog-
raphy (HPLC), with an ion-exchange column or electrophoresis 
methods. The HPLC measurement is considered the “gold stand-
ard” and is useful for assessing sensitivity and specificity of  other 
testing methods.
Differentiation between thalassemic and non-thalassemic micro-
cytosis has important clinical implications, because each has en-
tirely different cause, pathogenesis, prognosis and treatment. 
As in all chronic diseases prevention is important for the overall 
management of  the disease; the real danger of  non-diagnosis or 
misdiagnosis of  the carriers of  thalassemia trait is the potential 
homozygous offspring: appropriate screening, detection of  pa-
tients and counselling of  couples at risk are the most important 
procedures for reducing morbidity and mortality of  thalassemia 
patients.
IDA and thalassemia have different ethiologies, which result in 
typical profiles of  the hemogram: erythrocytosis and microcytosis 
in thalassemia carriers, anisocytosis in iron deficiency. Neverthe-
less, the profiles may show considerable overlap and hence it is 
difficult to recognise a carrier in daily practice based on individual 
parameters of  the hemogram only.
A discriminant formula or index based on red cells parameters 
derived from automated blood cell analyzers, with a high level of  
specificity and sensitivity for detecting thalassemia trait, would be 
a useful tool in the investigation of  microcytic anemia. In particul-
er in geographic areas where nutritional deficiencies and thalas-
semia do occur with high prevalence, such discriminant indices 
are of  great interest [6].
The usefulness of  these indices is to detect β-thalassemia car-
riers with a high probability. Therefore, the best index must 
have the highest sensitivity possible, in order to detect (almost) 
all β-thalassemia carriers. On the other hand, specificity must be 
good enough to avoid the measurement of  HbA2 in samples that 
do not need to undergo further analysis (false positives).
Suspicious samples can be selected for HbA2 analysis, to confirm 
the presumptive diagnosis of  the disease. β-Thalassemia can be 
diagnosed with confidence when raised HbA2, erythrocytosis, mi-
crocytosis and normal serum ferritin are present.
In the developing countries, where these diseases are endemic, 
represent a problem of  public health; but in the developed coun-
tries with the general budgetary reductions, the presumptive 
identification of  Hemoglobin disorders must rely on inexpensive 
methods of  detection, to allow an efficient use of  the resources 
RBC indices are useful tools, adding in the selection of  highly 
suspicious samples for further analysis, more sophisticated and 
expensive.
RBC indices can be calculated from data reported by the analyzers 
so every laboratory can apply this strategy, improving productiv-
ity, adding value and quality to the Laboratory reports.
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